Sign in
Taking people in United StatesPhase 1/2

Tests CELZ-201 for recently diagnosed type 1 diabetes in adults

Tests CELZ-201 given into an artery in adults recently diagnosed with type 1 diabetes.

Key facts

Who runs it
Creative Medical Technology Holdings Inc
Where
Miami, United StatesSee the site
Trial code
Registry title
Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes
Status
Recruiting
Phase
Phase 1/2
People taking part
18 people, planned
Started
7 Apr 2023
Expected to end
31 Jan 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • CELZ-201 Administration
  • Control Group
Record updated
19 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18-35 with Type 1 diabetes diagnosed within the last year, who still make some of their own insulin.

Age
18-35 years
Sex
Men and women can join.
Disease stage
Type 1 diabetes diagnosed within 1 year, confirmed by at least two islet autoantibodies (GAD65, IA-2 or ZnT8). Stimulated C-peptide peak level above 0.6 ng/mL on a 4-hour MMTT. eGFR above 80 ml/min/1.73m2.
Earlier treatment
Must follow standard-of-care diabetes management. Cannot have used diabetes medicines other than insulin. Cannot have had immunosuppressive treatment less than 3 months before randomization. Cannot have taken part in earlier clinical studies, other than observational ones.
Biomarker or test result
At least two islet autoantibodies (GAD65, IA-2 or ZnT8) and stimulated C-peptide peak level above 0.6 ng/mL.

Main reasons for not taking part

  • BMI above 28 kg/m or HbA1c above 9% (75 mmol/mol)
  • Any history of heart disease, liver disease or clotting problems
  • Pregnancy, breastfeeding, or not using reliable contraception
  • Active infection, or chronic infection such as hepatitis B, hepatitis C, tuberculosis or HIV
  • History of cancer (except localized basal or squamous cell skin cancer) or an organ transplant (allograft)

The registry criteria, word for word

Show all 40 criteriaShow less

Who can take part

  • Subject must be able to understand and provide signed informed consent
  • Males and females, 18-35 years of age
  • Diagnosis of T1D within 1 year, with stimulated C-peptide peak level >0.6 ng/mL as assessed by 4-hour MMTT at the time of Visit 0 (screening)
  • Diagnosed with T1D, according to ADA standard criteria, and confirmed by positivity to at least two islet autoantibodies, GAD65, IA-2, or ZnT8
  • Mentally stable and able to comply with the procedures of the study protocol
  • Subjects must be willing to comply with "standard-of-care" diabetes management
  • Subjects with eGFR >80 ml/min/1.73m2
  • Female subjects of childbearing potential must have a negative pregnancy test upon study entry
  • Female (and male) subjects with reproductive potential must agree to use two FDA approved methods of birth control for the entire duration of the study; Potential subjects of childbearing potential should agree to use effective contraception for the entire 2-year period
  • Adequate venous access to support study required blood draws

Who cannot take part

  • Subjects with any history of cardiac disease, including but not limited to myocardial infarction, uncompensated heart failure, fluid overload, as well as any clinically significant abnormality identified on prior cardiac stress test, angiogram evaluation, or echocardiogram
  • Recent recipient of any licensed or investigational live attenuated vaccine(s) within 6 weeks of randomization
  • Patients who have participated in previous clinical studies, other than observational studies, will be excluded
  • Concomitant therapy with immunosuppressive drugs, immunomodulators, or cytotoxic agents, or previous therapy less than 3 months from randomization
  • Diagnosed or self-reported drug or alcohol abuse
  • Known history of serious allergic reactions, including anaphylaxis to CELZ-201 or its preparation components. Specifically, patients with a prior history of heparin induced thrombocytopenia or any other adverse reaction to heparin, will be excluded
  • Subjects with poorly controlled hypertension as defined by systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg
  • Subjects with liver disease, portal hypertension, any coagulopathy (including history of Factor V deficiency) or long-term anti-coagulant therapy (except low-dose aspirin). Other hepatic conditions including hepatic anatomic abnormalities or variants that would place the individual at increased risk in the judgment of the investigator are also considered exclusionary
  • Symptomatic cholecystolithiasis; acute or chronic pancreatitis; or current symptomatic peptic ulcer disease
  • Subjects with uncontrolled thyroid disease: thyroid stimulating hormone <0.3 mU/L or >5 mU/L; free T4 <5.0 ug/dL or >11.0 ug/dL
  • Ongoing acute infections, e.g., acute respiratory tract, urinary tract, or gastrointestinal tract infections
  • Subjects with eating disorders
  • Ongoing or anticipated use of diabetes medications other than insulin
  • History or diagnosis of malignancy with the exception of a history of localized basal or squamous cell carcinoma
  • Any history of gastroparesis or other severe gastrointestinal disease
  • An individual who has a medical, psychological or social condition that, in the opinion of the Principal Investigator, would interfere with safe and proper completion of the trial
  • Positive for coronavirus disease (COVID)-19 by PCR or evidence of active infection per local institutional standards
  • Allergy to iodine contrast or anesthesia
  • HbA1c > 9%
  • Any of the following laboratory findings: hemoglobin <11.5 g/dL (females) or <13.2 g/dL (males); leukocytes <3,000/μL; neutrophils <1,500/μL; lymphocytes <800/μL; platelets <100,000/μL; elevation in AST and ALT >2 x ULN (upper limit of normal); LDL cholesterol >160; Triglycerides >3 x ULN; total bilirubin >1.5 x ULN
  • Screening laboratory evidence consistent with significant chronic active infection (i.e.., hepatitis B and C, tuberculosis, and HIV), and IGRA Tuberculosis (Tb) test during screening
  • Pregnancy or ongoing breastfeeding for women; unwillingness or inability of both females and males of childbearing age to use a reliable and effective form of contraception, for the entire 2-year duration of the study
  • Inability or unwillingness of a subject to give written informed consent or comply with study protocol
  • BMI>28 kg/m
  • Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within 7 days of screening
  • Presence of an allograft
  • Inability to perform any of the assessments required for endpoint analysis
  • The investigator believes that participating in the trial is not in the best interest of the patient, or the investigator considers patient unsuitable for enrollment (such as unpredictable risks or subject compliance issues)
  • For female subjects: Pregnant, nursing, or planning to become pregnant during the course of entire duration of the study (approximately little over two years) or unwillingness to comply with contraceptive requirements
  • For male subjects: Male subjects with a female partner who is planning to become pregnant with the male subject during the entire course of the study or unwillingness to comply with contraceptive requirements

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 35 years old?

Where in United States

  • Diabetes Research Institute, University of Miami Miller School of MedicineMiami, United StatesContact: Francesco Vendrame, MDTaking people

About the trial

What the trial wants to find out

The brief purpose of this research study is to learn about the safety and efficacy of intra-arterial administration of CELZ-201 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D).

The 2 groups in the trial

  • CELZ-201 Treatment GroupTreatment being tested

    Participants in this group will receive a single dose of CELZ-201, in addition to standard of care of care for Type 1 Diabetes treatment.

    Treatment: CELZ-201 Administration

  • Control GroupPlacebo, for comparison

    Participants in this group will receive standard of care for Type 1 Diabetes only.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Trial to Evaluate the Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes (CREATE-1)
Plain-language title
Tests CELZ-201 for recently diagnosed type 1 diabetes in adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05626712, who can take part
Record updated
19 February 2026